Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: Phase III multinational study results

Respirology

Volumn 18, Issue 5, 2013, Pages 866-873

  Fukuchi, Yoshinosuke ^a   Samoro, Ronnie ^d   Fassakhov, Rustem ^e   Taniguchi, Hiroyuki ^b   Ekelund, Jan ^f   Carlsson, Lars Goran ^f   Ichinose, Masakazu ^c  

^a JUNTENDO UNIVERSITY   (Japan)

^b TOSEI GENERAL HOSPITAL   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Healthlink Medical Surgical Dental Clinics and Diagnostic Center   (Philippines)

^e Kazan Research Institute of Epidemiology and Microbiology   (Russian Federation)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

budesonide formoterol; chronic obstructive pulmonary disease; exacerbation; formoterol; lung function

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FORMOTEROL; SALBUTAMOL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; BRONCHITIS; BRONCHOPNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALER; ISCHEMIC COLITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME VARIABLE; PHASE 3 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; BUDESONIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84879340207     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12090     Document Type: Article

References (19)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop summary [updated 2011]. [Accessed 15 Apr 2013.] Available from URL: http://www.goldcopd.com
2. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 912-919.
3. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009; 69: 549-565.
4. Sharafkhaneh A, Southard JG, Goldman M, et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir. Med. 2012; 106: 257-268.
5. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74-81.
6. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008; 68: 1975-2000.
7. Idolor LF, De Guia TS, Francisco NA, et al. Burden of obstructive lung disease in a rural setting in the Philippines. Respirology 2011; 16: 1111-1118.
8. Minakata Y, Ichinose M,. Epidemiology of COPD in Japan [in Japanese]. Nihon Rinsho 2011; 69: 1721-1726.
9. Tan WC,. Trends in chronic obstructive pulmonary disease in the Asia-Pacific regions. Curr. Opin. Pulmon. Med. 2011; 17: 56-61.
10. Yoo KH, Kim YS, Sheen SS, et al. Prevalence of chronic pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011; 16: 659-665.
11. Bogdan MA, Aizawa H, Fukuchi Y, et al. Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: phase III study results. BMC Pulmon. Med. 2011; 11: 51.
12. Minakata Y, Lijima H, Takahashi T, et al. Efficacy and safety of formoterol in Japanese patients with COPD. Intern. Med. 2008; 47: 217-223.
13. Partridge MR, Karlsson N, Small IR,. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr. Med. Res. Opin. 2009; 25: 2043-2048.
14. Jones PW,. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur. Respir. J. 2002; 19: 398-404.
15. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009; 6: 320-329.
16. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir. Med. 2008; 102: 1099-1108.
17. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-789.
18. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 175: 144-149.
19. Sin DD, Tashkin D, Radner F, et al. An update on the risk of pneumonia related to budesonide use in COPD: pooled analysis. Am. J. Respir. Crit. Care Med. 2012; 185: A2945.